STOCK TITAN
  1. Home
  2. Sec-filings
  3. TELO
  4. [8-K] Telomir Pharmaceuticals, Inc. Reports Material Event

[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock TELO logo
Telomir Pharms

NASDAQ:TELO

TELO Rankings

#5372 Ranked by Market Cap
N/A Ranked by Dividends

TELO Latest News

Aug 28, 2025
Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases
Aug 7, 2025
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction
Jul 24, 2025
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's
Jul 18, 2025
Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin
Jun 18, 2025
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

TELO Latest SEC Filings

Aug 27, 2025
[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event
Aug 7, 2025
[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event
Jul 23, 2025
[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event
Jul 22, 2025
[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event

TELO Stock Data

42.61M
22.11M
31.5%
8.73%
5.16%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI